Tempus to acquire Personalis for $1.5 billion
Tempus to acquire Personalis for $1.5 billion July 20 (Reuters) - Tempus AI TEM.O said on Monday it would acquire Personalis PSNL.O for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm's oncology portfolio.
(Reporting by Christy Santhosh in Bengaluru; Editing by Anil D'Silva)
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb